Valuation: Forte Biosciences, Inc.

Market Cap 514M 451M 415M 389M 729M 48.48B 744M 4.99B 1.93B 23.96B 1.93B 1.89B 83.08B P/E 2026 *
-5.12x
P/E 2027 * -4.95x
Enterprise Value 514M 451M 415M 389M 729M 48.48B 744M 4.99B 1.93B 23.96B 1.93B 1.89B 83.08B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.87%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Forte Biosciences, Inc.

1 day+1.95%
1 week+16.74%
Current month+11.90%
1 month+11.90%
3 months-18.92%
6 months-18.14%
Current year-21.75%
1 week 16.89
Extreme 16.89
21.69
1 month 15.51
Extreme 15.51
21.69
Current year 15.51
Extreme 15.51
35.8
1 year 9.1
Extreme 9.1
35.8
3 years 4.11
Extreme 4.11
35.8
5 years 4.11
Extreme 4.11
921.25
10 years 4.11
Extreme 4.11
1,349.75
Manager TitleAgeSince
Chief Executive Officer 55 01/01/2018
Director of Finance/CFO 59 01/03/2020
Chief Operating Officer - 01/10/2020
Director TitleAgeSince
Chairman 55 -
Director/Board Member 58 01/06/2020
Director/Board Member 79 16/03/2022
Date Insider Type Main position Quantity % Market Cap.
16/06Free

Chief Executive Officer

500,000 2.4415%
16/06Free

Chief Financial Officer

22,000 0.1074%
29/05Free

Director

18,353 0.0896%
Change 5-day change 1-year change 3-year change Capi.($)
+1.95%+16.74%+65.04%-15.06% 514M
+0.76%-0.70%+68.24%+123.34% 55.63B
+6.76%+22.83%+91.66%+101.42% 52.25B
+1.45%+2.24%-13.39%-13.82% 23.07B
+1.30%+5.86%+3.72%+413.68% 22.41B
+6.78%+14.47%+40.28%-6.67% 17.32B
+0.97%+3.81%+30.68%-32.21% 15.94B
+0.50%+7.86%+25.66%+192.11% 13.77B
+9.96%+19.81%+157.65%+320.70% 13.47B
+4.21%+4.76%+33.21% - 12.43B
Average +3.47%+7.94%+50.28%+120.39% 22.68B
Weighted average by Cap. +3.47%+7.64%+54.98%+127.99%

Financials

2026 *2027 *
Net sales - -
Net income -95.54M -83.77M -77.21M -72.29M -136M -9.01B -138M -928M -359M -4.45B -359M -351M -15.44B -130M -114M -105M -98.69M -185M -12.3B -189M -1.27B -490M -6.08B -490M -479M -21.09B
Net Debt - -
Logo Forte Biosciences, Inc.
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Employees
22
Date Price Change Volume
30/06/26 USD 21.34 +1.45% 85,049
26/06/26 USD 21.03 +12.40% 3,079,361
25/06/26 USD 18.71 +0.92% 186,507
24/06/26 USD 18.54 +2.15% 217,126
23/06/26 USD 18.15 -0.71% 348,196
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
21.03USD
Average target price
63.75USD
Spread / Average Target
+203.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBRX Stock